Raysearch Laboratories
In this equity research report, analysts Vilmer Larsson and Meja Wessman take a closer look at RaySearch Laboratories, a leading software provider in cancer treatment. Holding a 50% market share in proton therapy software and advancing adaptive therapy tools, RaySearch is positioned to benefit from a market growing at a 13% CAGR until 2033E. A target price of SEK 284, derived from an equally weighted DCF and peer valuation, indicates a 32% upside.